Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Ancona – page 22

377 clinical trials in Ancona, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ancona at a glance
377
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

377 trials in Ancona

Open in trial search

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Universita' Degli Studi Di Torino

Neoplasm malignant

Not recruiting

Study on the Safety of Avelumab, Lorlatinib, and Axitinib for Cancer Patients Continuing from Previous Trials

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Avelumab
  • Sponsor:Pfizer Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Fondazione European Myeloma Network Italy O.N.L.U.S.

Pulmonary fibrosis

Not recruiting

Study of Inhaled Pirfenidone for Patients with Progressive Pulmonary Fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Avalyn Pharma Inc.

Chronic spontaneous urticaria

Not recruiting

Study of remibrutinib for long-term treatment of adult patients with chronic spontaneous urticaria who completed previous remibrutinib studies

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Cholangiocarcinoma

Not recruiting

Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Incyte Corp.

Spinal muscular atrophy

Not recruiting

Study on the Safety and Efficacy of RO7204239 and Risdiplam for Patients with Spinal Muscular Atrophy

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Sponsor:F. Hoffmann-La Roche AG

Idiopathic pulmonary fibrosis

Not recruiting

Study on the Effects of Inhaled Treprostinil for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Urticaria chronic+2

Not recruiting

Study on Remibrutinib for Adults with Chronic Inducible Urticaria Uncontrolled by H1-Antihistamines

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Cutaneous lupus erythematosus

Not recruiting

Study on Anifrolumab for Adults with Chronic or Subacute Cutaneous Lupus Erythematosus Unresponsive to Antimalarial Therapy

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Squamous cell carcinoma of head and neck

Not recruiting

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Mantle cell lymphoma

Not recruiting

Study on Rituximab, Bendamustine, Cytarabine, and Venetoclax for High-Risk Elderly Patients with Mantle Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione Italiana Linfomi Ets

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Ancona

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on metastatic colorectal cancer and various advanced cancers including gastric cancer and non-small cell lung cancer. Studies evaluate novel treatment combinations and targeted therapies.

  • Colorectal Cancer Treatments
  • Gastric Cancer Therapies
  • Lung Cancer Innovations

Multiple studies examining new therapeutic approaches for pancreatic adenocarcinoma and advanced solid tumors.

02 Hematologic Disorders

Comprehensive research into blood disorders, including multiple myeloma and chronic myeloid leukemia. Studies focus on novel treatment combinations and targeted therapies.

  • Leukemia Treatments
  • Multiple Myeloma Therapies
  • Stem Cell Transplantation

Evaluation of new therapeutic approaches for various blood cancers and related conditions.

03 Dermatology & Rheumatology

Clinical studies investigating treatments for psoriatic arthritis, hidradenitis suppurativa, and atopic dermatitis. Focus on innovative biological therapies.

  • Inflammatory Skin Conditions
  • Autoimmune Disorders
  • Joint Diseases

Research aimed at improving treatment outcomes for chronic inflammatory conditions.

04 Respiratory Medicine

Studies evaluating treatments for progressive pulmonary fibrosis and severe asthma. Research focuses on improving lung function and disease management.

  • Pulmonary Fibrosis
  • Asthma Management
  • Respiratory Conditions

Development of innovative therapies for chronic respiratory diseases.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.